Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:18:17 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:AVXL from 2023-05-04 to 2024-05-03 - 35 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
2024-04-11 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
2024-03-25 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
2024-03-19 15:50U:AVXLNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Anavex Life Sciences Corp. - AVXL
2024-03-18 07:30U:AVXLNews ReleaseAnavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX(TM)3-71 in Schizophrenia
2024-02-26 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
2024-02-07 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports ‚  Fiscal 2024 First Quarter Financial Results and Provides Business Update
2024-02-01 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
2024-01-24 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports Publication of ANAVEX ‚ ®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX ‚ ®3-71 in Humans
2024-01-16 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX ‚ ®3-71 in Schizophrenia
2024-01-08 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX ‚ ®2-73) for Treatment of Neurodevelopmental Disorders
2024-01-03 07:30U:AVXLNews ReleaseAnavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 08:00U:AVXLNews ReleaseAnavex Life Sciences Provides an Update on Rett Syndrome Program
2023-12-20 07:30U:AVXLNews ReleaseAnavex Announces First Entire Clinical Gene Pathway Data of ANAVEX ‚ ®2-73 from AVATAR Study in Patients with Rett Syndrome
2023-12-19 07:30U:AVXLNews ReleaseAnavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer ¢ € ™s Disease
2023-11-27 08:00U:AVXLNews ReleaseAnavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
2023-11-24 08:00U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
2023-11-22 08:00U:AVXLNews ReleaseAnavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX ‚ ®2-73) for Treatment of Insomnia or Anxiety
2023-11-20 08:00U:AVXLNews ReleaseAnavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer ¢ € ™s Disease to European Medicines Agency (EMA)
2023-11-06 08:00U:AVXLNews ReleaseAnavex Life Sciences Appoints Senior VP of Regulatory Affairs
2023-10-25 08:00U:AVXLNews ReleaseAnavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX ‚ ®3-71 to Prevent Cognitive Decline in Alzheimer ¢ € ™s Disease
2023-09-14 07:30U:AVXLNews ReleaseAnavex ¢ € ™s Phase 2b/3 Trial of Blarcamesine (ANAVEX ‚ ®2-73) in Patients with Alzheimer ¢ € ™s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
2023-09-12 07:30U:AVXLNews ReleaseAnavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board
2023-08-08 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
2023-08-07 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports Publication of ANAVEX ‚ ®3-71 in Clinical Journal Confirming ANAVEX ‚ ®3-71 Clinical Cardiovascular Safety
2023-08-02 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023
2023-08-01 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2023 Third Quarter Financial Results ‚  on Tuesday August 8, 2023
2023-06-28 07:30U:AVXLNews ReleaseLong-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX ‚ ®2-73 (blarcamesine) for Rett Syndrome
2023-06-27 07:30U:AVXLNews ReleaseAnavex Life Sciences and Partex Group Announce Strategic Partnership to Leverage AI for Drug Development and Healthcare Sales Marketing Building a Patient-Centric Digital Ecosystem
2023-06-20 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
2023-06-15 07:30U:AVXLNews ReleaseANAVEX ‚ ®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome
2023-06-12 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports Publication in Medical Journal Signifying Continued Commitment for Improvement of the Rett Syndrome Caregiver Outcome Measure RSBQ
2023-06-06 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Completion of ANAVEX( ‚ ®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
2023-06-01 07:30U:AVXLNews ReleaseANAVEX Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX ‚ ®2-73 (blarcamesine)
2023-05-09 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports ‚  Fiscal 2023 Second Quarter Financial Results